BI
LGND icon

Binnacle Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Binnacle Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$886 Hold
5
– – ﹤0.01% 772
2025
Q2 		$568 Hold
5
– – ﹤0.01% 758
2025
Q1 		$526 Buy
+5
New +$565 ﹤0.01% 696

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Binnacle Investments's LGND Position: Q3 2025 in Review

Binnacle Investments held its Ligand Pharmaceuticals (LGND) position steady in Q3 2025 at 5 shares worth $886. The position accounts for ﹤0.01% of the portfolio, ranked #772.

Binnacle Investments first reported a position in LGND in Q1 2025 and has held it in 3 quarters since. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

  • Binnacle Investments held 5 shares of Ligand Pharmaceuticals worth $886 as of Q3 2025.
  • Binnacle Investments left its Ligand Pharmaceuticals share count unchanged in Q3 2025.
  • Ligand Pharmaceuticals made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #772 holding.
  • Binnacle Investments first reported a position in Ligand Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.